Trial
NCT03948334
A Study to Assess the Safety and Efficacy of ZPL389 With TCS/TCI in Atopic Dermatitis Patients
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Novartis Pharmaceuticals
Collaborators
—
Condition
Atopic Dermatitis
Intervention
ZPL389 30mg
Why stopped
Core terminated due to lack of efficacy
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-10-08